Yerevan
Tbilisi
Moscow
Paris
Los Angeles
Beijing
English
Հայերեն Русский
Main Timeline Video Share
May the Holiday Warm Hearts: Idram and IDBank Support the Children of Heroes Beneficiaries of the "By Your Side" program at IDBank AraratBank Named Large CSR Company of the Year Idram Joins the Fight Against Food Insecurity Ucom’s Renovated Sales and Service Center in Yerevan Mall Reopens 1% idcoin instead of New Year’s suffering: practical tips Idram Junior Donated Books to Schools Big Christmas Market with Idram, IDBank and idplus Ucom Supports Wildlife Monitoring in Ararat Region IDBank, Idram, and idplus at the Big Christmas Market Converse Bank Deputy CEO and CFO, Grant Akopian, Elected to BACEE Board Ucom and SunChild NGO Install a Solar Plant in Alaverdi Kindergarten
Timeline
Ucom Continues Large-Scale Network Modernization, Expanding 5G Coverage and Enhancing Connectivity EBRD’s AMD-denominated bonds listed on AMX; Converse Bank acted as underwriterBecome a Unibank shareholder and acquire perpetual bonds with a 13.25% yieldThe Unprecedented Educational Summer of the 'Armenian Virtuosos'All Armflix Content Is Once Again Available on UplayHayk Melikyan Opens the 5th Festival of Armenian Culture in KatowiceHarutyun Harutyunyan: “The Government Has No Intention of Applying for EU Membership and Adopted the Law to Prevent a Referendum”Ucom Supports Coca-Cola Fest 2026 “Orran” Students Start the New Academic Year with Support from “The Power of One Dram”It is with deep awareness of the seriousness of this supposition as well as concern that we pose the question of the above headline“Armenian Virtuosos” Scholarship Recipients Take the Stage at the 4th International Festival of Youth Orchestras of the WorldUnibank Launches a New Promotion "U-Teenager": Grand Prize — a Summer Course at One of the Top Universities AbroadSEROOND Begins: Armenia’s First Authored School Model Based on Whole-Child Development, Enabled by AI"Unisport" Advances to the Main Round of the UEFA Futsal Champions League Cybersecurity Course Graduates Take Part in Ucom’s “Junior Academy” ProgramUcom Introduces Green Tariff Plans, Turning Everyday Connectivity into Environmental Impact Ucom Launches “Unity Back to School” Special Offer for the New School YearUcom’s Sales and Service Center Reopens at 7 Sayat-Nova Street in Gyumri "Unisport" Competes in the UEFA Futsal Champions LeagueAram Barseghyan Appointed CEO of Team Telecom Armenia, Hayk Yesayan to Lead Team Group
All Timeline »
Life

Multiple sclerosis drug shows promising efficacy

The multiple sclerosis drug is showing promising efficacy in fighting relapses and reducing fatigue.

Back in March 2001, the US Food and Drug Administration approved a drug called ponosimod for use in adult patients with various types of multiple sclerosis. Only now there are research data that show that some drug reduces the number of relapses of the disease and can reduce fatigue - one of the characteristic symptoms of multiple sclerosis.

The respected scientific journal JAMA Neurology has found that ponesimod is more effective in fighting fatigue in multiple sclerosis than another commonly used drug called teriflunomide. It is superior to teriflunomide in reducing relapse rates and reducing the risk of new or existing lesions of myelin found on magnetic resonance imaging.

As reported by everydayhealth.com, ponesimod is used for various types of multiple sclerosis, including the most common relapsing remitting disease and active secondary progressive, which is the most severe. It is not accompanied by remissions and steadily leads to the disability of patients. It is people with this form of multiple sclerosis who show the appearance of new lesions of the myelin layer on MRI scans. Ponesimod must be taken once a day, treatment begins with a period of 14 days, then the doses are increased.